Italicized product names are trademarks of Bristol-Myers Squibb Company or one of its divisions or subsidiaries. Abilify is a trademark of Otsuka Pharmaceutical Co., Ltd. Erbitux is a trademark of ImClone Systems Incorporated. EMSAM is a trademark of Somerset Pharmaceuticals, Inc. Glucophage, Glucovance and Metaglip are trademarks of Merck Santé S.A.S., an associate of Merck KGaA of Darmstadt, Germany. Avapro, Avalide and Plavix are trademarks of sanofi-aventis. Sinemet CR is a trademark of Merck & Co., Inc.

© 1999-2008 Bristol-Myers Squibb Company. Your use of the information on this site is subject to the terms of our Legal Notice and Privacy Policy.

Stock Quote Disclaimer: Copyright © 1998-2002 MarketWatch.com Inc. User agreement applies. Historical and current end-of-day data provided by Interactive Data Corp. Intraday data is at least 20-minutes delayed. All times are EDT. Intraday data provided by S&P Comstock and subject to terms of use.

NYSE | BMY 19.32 | -1.11 | 4:01 PM EDT | 06 Oct 2008

Top Stories

Advanced Breast Cancer Community Portal New this month: We are proud to support this website for women to share experiences, information, clinical trials and treatment options.
View portal >>

We Are a Top 10 Best Company for Working Mothers For the eleventh consecutive year, Working Mother magazine has named Bristol-Myers Squibb as a Top 100 Best Company.
Read more >>

Latest News
10.06.2008>>Bristol-Myers Squibb Comments on Eli Lilly as New Erbitux Marketing Partner 10.02.2008>>Bristol-Myers Squibb Appoints Christopher Perley as Devens General Manager 10.01.2008>>U.S. Food & Drug Administration Approved the use of REYATAZ(R) (atazanavir sulfate) Boosted with Ritonavir, in Combination Therapy, for Previously Untreated HIV-1 Infected Adult Patients